Kaskela Law LLC is investigating Charles River Laboratories Intl. (NYSE: CRL) (“Charles River”) on behalf of the company’s long-term shareholders.

Recently a securities fraud complaint was filed against Charles River on behalf of certain investors who purchased shares of the company’s stock between May 7, 2020 and March 15, 2023.  According to the complaint, during that time period Charles River and certain of the company’s senior executives made a series of materially false and/or misleading statements about the company’s procurement of non-human primates (“NHPs”), and in particular, long-tailed macaques, from inherently suspicious suppliers.

On February 22, 2023, Charles River revealed that it had received a subpoena from the U.S. Department of Justice relating to an ongoing criminal investigation in conjunction with the U.S. Fish and Wildlife Service into the supply chain and trafficking of NHPs into the U.S. for research.  On this news, Charles River’s stock price fell $24.51 per share, or over 10% in value, to close at $219.09 per share on February 22, 2023.

Then, on March 15, 2023, Charles River’s CEO admitted that the company “used non-preferred suppliers of long-tailed macaques from Cambodia: So there are no U.S. breeding sources. There are a couple of companies that sort of brokers that get animals from wherever. We have used those folks to some extent historically. … We prefer not to use them. Reputationally, I just don’t think they’re the best possible people to use. And I don’t actually think they care where the animals come from or what the background is.”  On this news, Charles River’s stock price fell an additional $10.12 per share, or 5% in value, to close at $194.90 per share on March 15, 2023.

The investigation seeks to determine – on behalf of the company’s current shareholders – whether the members of Charles River’s board of directors violated the securities laws and/or breached their fiduciary duties in connection with the above alleged misconduct.

Current Charles River shareholders who purchased or acquired CRL shares prior to May 7, 2020 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (888) 715 – 1740 or (484) 229 – 0750, or by completing the form on this page, for additional information about this investigation and their legal rights and options.